Bio­gen leaps in­to a show­down be­tween Roche and Re­gen­eron, bet­ting on a po­ten­tial new fran­chise play­er

Plagued by a woe­ful launch for its Alzheimer’s fran­chise, Bio­gen is bet­ting $30 mil­lion on some re­li­able part­ners at Genen­tech to come up with a fast new fran­chise drug — out­side of its CNS spe­cial­ty.

The ther­a­py is mo­sune­tuzum­ab, a “break­through” des­ig­nate at the FDA which looks per­fect­ly po­si­tioned for a shot at an ac­cel­er­at­ed ap­proval. Work­ing on their long­time col­lab­o­ra­tion on CD20, Bio­gen will chip in on some of last year’s R&D work and add a $30 mil­lion pay­ment to step in to co-com­mer­cial­ize the drug.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters